High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance

References

• Alaaeddine N, DiBattista JA, Pelletier JP, Cloutier JM, Kiansa K, Dupuis M, et al. 1997. Osteoarthritic synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF-R55) that mediates biological activation by TNF-alpha. J Rheumatol 24(10):1985–1994.
   PubMed Web of Science ®Google Scholar
• Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell'osso B, et al. 2013. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42:1–4.
   PubMed Web of Science ®Google Scholar
• Asevedo E, Gadelha A, Noto C, Mansur RB, Zugman A, Belangero SI, et al. 2013. Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. J Psychiatr Res 47(10):1376–1382.
   PubMed Web of Science ®Google Scholar
• Asevedo E, Rizzo LB, Gadelha A, Mansur RB, Ota VK, Berberian AA, et al. 2014. Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiol Behav 129:194–198.
   PubMed Web of Science ®Google Scholar
• Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. 2012. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37(12):1901–1911.
   PubMed Web of Science ®Google Scholar
• Bresee C, Rapaport MH. 2009. Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int J Neuropsychopharmacol 12(6):861–865.
   PubMed Web of Science ®Google Scholar
• Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. 2009. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 23(8):1079–1j082.
   PubMed Web of Science ®Google Scholar
• Coelho FM, Reis HJ, Nicolato R, Romano-Silva MA, Teixeira MM, Bauer ME, et al. 2008. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 15(2):140–144.
   PubMed Web of Science ®Google Scholar
• Davis J, Moylan S, Harvey BH, Maes M, Berk M. 2014. Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. Aust N Z J Psychiatry 48(6):512–529.
   PubMed Web of Science ®Google Scholar
• Dean B. 2011. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 14(7):997–1012.
   PubMed Web of Science ®Google Scholar
• Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. 2006. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20(6):532–545.
   PubMed Web of Science ®Google Scholar
• Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168(7):3195–3204.
   PubMed Web of Science ®Google Scholar
• Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. 1997. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247(4):228–233.
   PubMed Web of Science ®Google Scholar
• Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YA, et al. 2006. Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology 66(1):146–147.
   PubMed Web of Science ®Google Scholar
• Grassi-Oliveira R, Brieztke E, Teixeira A, Pezzi JC, Zanini M, Lopes RP, et al. 2012. Peripheral chemokine levels in women with recurrent major depression with suicidal ideation. Rev Bras Psiquiatr 34(1):71–75.
   PubMed Web of Science ®Google Scholar
• Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, et al. 2009. Reproducibility of serum cytokines and growth factors. Cytokine 45(1):44–9.
   PubMed Web of Science ®Google Scholar
• Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, et al. 1999. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33(5):407–418.
   PubMed Web of Science ®Google Scholar
• Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. 2009. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 11(7):726–734.
   PubMed Web of Science ®Google Scholar
• Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, et al. 2013. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 145(1–3):36–42.
   PubMed Web of Science ®Google Scholar
• Kim YK, Kim L, Lee MS. 2000. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44(3):165–175.
   PubMed Web of Science ®Google Scholar
• Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, et al. 2002. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 7(10):1107–1114.
   PubMed Web of Science ®Google Scholar
• Kubera M, Kenis G, Bosmans E, Scharpe S, Maes M. 2000. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology 23(1):89–98.
   PubMed Web of Science ®Google Scholar
• Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura GJ, Pioli R, et al. 2002. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54(3):281–291.
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M, et al. 1996. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 21(1):39–50.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70(7): 663–671.
   PubMed Web of Science ®Google Scholar
• Monji A, Kato T, Kanba S. 2009. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63(3):257–265.
   PubMed Web of Science ®Google Scholar
• Monteleone P, Fabrazzo M, Tortorella A, Maj M. 1997. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71(1):11–17.
   PubMed Web of Science ®Google Scholar
• Moreira MA, Souza AL, Lana-Peixoto MA, Teixeira MM, Teixeira AL. 2006. Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis. Braz J Med Biol Res 39(4):441–445.
   PubMed Web of Science ®Google Scholar
• Mundo E, Altamura AC, Vismara S, Zanardini R, Bignotti S, Randazzo R, et al. 2005. MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am J Med Genet B Neuropsychiatr Genet 132B(1):1–4.
   PubMed Web of Science ®Google Scholar
• Noto C, Gadelha A, Belangero SI, Spindola LM, Rocha NP, de Miranda AS, et al. 2013. Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. J Psychiatr Res 47(4):467–471.
   PubMed Web of Science ®Google Scholar
• Noto CS, Gadelha A, Belangero SI, Smith MA, de Aguiar BW, Panizzuti B, et al. 2011. Association of biomarkers and depressive symptoms in schizophrenia. Neurosci Lett 505(3):282–285.
   PubMed Web of Science ®Google Scholar
• Noto C, Ota VK, Gouvea ES, Rizzo LB, Spindola LM, Honda PH, et al. 2014. Effects of risperidone on cytokine profile in drug-naive first-episode psychosis. Int J Neuropsychopharmacol 18(4).
   PubMed Web of Science ®Google Scholar
• Noto C, Ota VK, Santoro ML, Ortiz BB, Rizzo LB, Higuchi CH, et al. 2015. Effects of depression on the cytokine profile in drug naive first-episode psychosis. Schizophr Res.
   Web of Science ®Google Scholar
• O'Grady NP, Tropea M, Preas HL 2nd, Reda D, Vandivier RW, Banks SM, et al. 1999. Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis. J Infect Dis 179(1):136–141.
   PubMed Web of Science ®Google Scholar
• Pae CU, Yoon CH, Kim TS, Kim JJ, Park SH, Lee CU, et al. 2006. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol 6(4):666–671.
   PubMed Web of Science ®Google Scholar
• Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC, et al. 2012. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46(6):819–824.
   PubMed Web of Science ®Google Scholar
• Pollmacher T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J. 1997. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 154(12):1763–1765.
   PubMed Web of Science ®Google Scholar
• Pollmacher T, Hinze-Selch D, Mullington J. 1996. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16(5):403–409.
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63(8): 801–808.
   PubMed Web of Science ®Google Scholar
• Rankin SM, Conroy DM, Williams TJ. 2000. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 6(1):20–27.
   PubMedGoogle Scholar
• Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, et al. 2011. Dysregulation of chemo- cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 12:13.
   PubMed Web of Science ®Google Scholar
• Reaux-Le Goazigo A, Van Steenwinckel J, Rostene W, Melik Parsadaniantz S. 2013. Current status of chemokines in the adult CNS. Prog Neurobiol 104:67–92.
   PubMed Web of Science ®Google Scholar
• Rostene W, Kitabgi P, Parsadaniantz SM. 2007. Chemokines: a new class of neuromodulator? Nat Rev Neurosci 8(11): 895–903.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Lu L, Saxena R. 1999. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259(2): 344–348.
   PubMed Web of Science ®Google Scholar
• Schizophrenia Working Group of the Psychiatric Genomics C. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427.
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Muller N, Riedel M, Ackenheil M. 2001. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 56(4):483–486.
   PubMed Web of Science ®Google Scholar
• Smith RS, Maes M. 1995. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 45(2):135–141.
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Baune BT. 2014. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev 42:93–115.
   PubMed Web of Science ®Google Scholar
• Teixeira AL, Reis HJ, Nicolato R, Brito-Melo G, Correa H, Teixeira MM, et al. 2008. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32(3):710–714.
   PubMed Web of Science ®Google Scholar
• Tourjman V, Kouassi E, Koue ME, Rocchetti M, Fortin-Fournier S, Fusar-Poli P, et al. 2013. Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res 151(1–3):43–47.
   PubMed Web of Science ®Google Scholar
• Upthegrove R, Manzanares-Teson N, Barnes NM. 2014. Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis. Schizophr Res 155(1–3): 101–108.
   PubMed Web of Science ®Google Scholar
• van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. 1999. Elevated interleukin-6 in schizophrenia. Psychiatry Res 87(2–3):129–136.
   PubMed Web of Science ®Google Scholar
• Wood SJ, Yung AR, McGorry PD, Pantelis C. 2011. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol Psychiatry 70(7):619–625.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. 2002. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 57(2–3):247–258.
   PubMed Web of Science ®Google Scholar